Skip to content

The effect of prophylactic use of pethidine for anxiety and post procedural pain relief in patients undergoing percutaneous liver biopsy

In patients undergoing percutaneous liver biopsy, do prophylactic use of pethidine, compared to no treatment, reduce the anxiety and post procedural pain relief

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12614001194651
Acronym
Nil
Enrollment
100
Registered
2014-11-13
Start date
2009-03-05
Completion date
2011-05-31
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Liver biopsy is an important procedure for the diagnosis and evaluation of liver disease and it can be associated with pain. For years this procedure was performed in Dunedin hospital without Pethidine give prior to the investigation. Two years ago we started giving pethidine immediately before a liver biopsy was performed. This was done to potentially decrease the amount of pain-relief required following the procedure. A recent analysis of our data indicated that this was indeed the case however, an unknown number of patients might have been given Pethidine unnecessarily because they never experienced any pain after the procedure. With this study we would like to assess how effective pre-procedural Pethidine is in controlling pain and anxiety during and after the procedure.

Interventions

Patients undergoing percutaneous liver biopsy receive 50mg of intravenous pethidine and 10mg of intravenous metoclopramide as premedication.

Sponsors

Gastroenterology unit, Dunedin Hospital
Lead SponsorHospital

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
16 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

All patients undergo percutaneous liver biopsy at Dunedin hospital

Exclusion criteria

1) Patients with previous allergic reaction to pethidine or metoclopramide; 2) Patients with clotting disorders and abnormal prothrombin time with international normalized ratio (INR) of greater than 1.5 or thrombocytopenia with platelet less than 50 x 109 per litre; 3) abdominal ultrasound revealed a contraindication to PLB such as massive ascites, intrahepatic duct dilatation, or focal lesion; 4) patients without a telephone for study follow up; and 5) patients with a solitary lesion that required target biopsy under ultrasound guidance

Outcome results

None listed

Source: ANZCTR · Data processed: Mar 18, 2026